Ingenuity Systems has announced that it has been awarded a new, five-year contract with Integromics, one of the foremost life science IT companies in Spain and the service provider to the Genomics, Proteomics and Bioinformatics Core Facility of Andalusia (Malaga, Spain).
Ingenuity Systems was selected by Integromics to be its sole pathways analysis provider, enabling the Andalusian Core Facility and all of its academic member organizations to use Ingenuity Pathways Analysis (IPA).
The Andalusian Core Facility provides scientists in public research institutions access to a powerful bioinformatic core infrastructure formed by supercomputing hardware facilities and state-of-the-art software. Integromics provides sophisticated software solutions for data management and data analysis in genomics, proteomics, and drug discovery.
From its scientific base, Integromics offers its clients a deep and current understanding of challenges, initiatives, and solutions related to life sciences. Integromics has formed important partnerships in industry and academia to develop technological solutions that enable clients to achieve their goals. Integromics is headquartered at the Business Entrepreneur Facilities for Life Sciences of Granada, Spain.
"Ingenuity Systems was selected because they offer the most comprehensive pathways solution, with the most extensive biological and chemical knowledge. IPA provides a great complementarity with other tools for functional analysis of genomic data like Integromic's ArrayUnlock(C). Additionally, IPA provides a remarkable add-on to our portfolio in secondary analysis as it is integrated with our Spotfire DecisionSite® modules for microarray analysis," commented Pedro A. de Alarcon, Business Development Director of Integromics.
"We are very pleased to have been selected by Integromics to support such a progressive initiative," stated Brian Dron, Director of European Operations at Ingenuity Systems. "We have earned the confidence of life science researchers through our commitment to quality, usability, and innovation. We are excited to expand our efforts in Spain by delivering these capabilities to support research groups in genomics, proteomics and drug discovery."